Haduvio™
We are dedicated to the development of Haduvio (oral nalbuphine ER) for the treatment of serious chronic cough conditions.
“On my worst days, coughing will wipe you out for
an entire day … Physically, you’re exhausted.”
Voice of the Patient Report: “Idiopathic Pulmonary Fibrosis”, March 2015.
“On my worst days, coughing will wipe you out for an entire day … Physically, you’re exhausted.”
Voice of the Patient Report: “Idiopathic Pulmonary Fibrosis”, March 2015.
Haduvio and Chronic Cough
Haduvio’s unique mechanism of action (MOA) that interacts with both the central and peripheral nervous systems, has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, we are focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough.
